EU HTA

Market Access

Whether a drug can secure reimbursement is pharma's billion-dollar question, and the companies that succeed will be those that answer it sooner.

Market Access

Unfortunately, much of the discussion around the JCA has focused on how the framework is intended to operate, rather than how it works in practice.

Market Access

Here, we examine the early realities of JCA implementation, exploring whether the system is delivering greater alignment across European markets.

Market Access

Rare disease launches are the ultimate stress test for European commercialisation.

Market Access

At ISPOR EU 2025, a cross-stakeholder panel addressed how Joint Clinical Assessment under the EU HTA Regulation is reshaping evidence strategies.

Market Access

New policies are shaping the market access landscape, such as the introduction of the EU HTA for oncology medicines.